Related Experiment Video
Updated: Feb 28, 2026

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W Mouw1,2,3, Michael S Goldberg2,4, Panagiotis A Konstantinopoulos2,5,6
1Department of Radiation Oncology, Brigham & Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies.Significance: Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair deficiency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. Cancer Discov; 7(7); 675-93. ©2017 AACR.
Insights
Tumor DNA repair deficiencies can enhance responses to immune checkpoint blockade therapy. Understanding DNA damage and genomic instability is key to developing predictive biomarkers for cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- DNA-damaging agents are utilized in cancer treatment, targeting tumor DNA repair deficiencies.
- Immune checkpoint blockade (ICB) is a growing therapeutic strategy in oncology.
- The interplay between tumor DNA damage and the immune system is increasingly recognized.
Purpose of the Study:
- To summarize mechanisms linking DNA damage and genomic instability to antitumor immune responses.
- To describe clinical applications of DNA repair biomarkers for guiding immunotherapy.
Main Methods:
- Review of existing literature on DNA damage, repair, and immune response.
- Analysis of clinical studies investigating DNA repair biomarkers and ICB efficacy.
Main Results:
- Tumor DNA repair landscape influences response to immune checkpoint blockade.
- Genomic instability and DNA repair deficiencies are associated with improved outcomes in ICB.
- DNA repair biomarkers show promise for predicting immunotherapy response.
Conclusions:
- Deficiencies in DNA repair can potentiate antitumor immunity and ICB efficacy.
- Genomic instability is a significant factor in shaping the tumor immune microenvironment.
- Biomarkers of DNA repair are crucial for personalizing cancer immunotherapy decisions.
More Related Videos
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
11:24Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
Published on: July 3, 2015
Related Concept Videos
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Overview of DNA Repair
Chemically...